Coley Pharmaceutical Group
Therapeutics and drug candidates to fight cancers, asthma, allergy and autoimmune disorders
About Coley Pharmaceutical Group
Coley Pharmaceutical Group operated as a biopharmaceutical company focused on developing a novel class of drug candidates known as TLR Therapeutics. The company was co-founded in 1997 by Dr. Arthur M. Krieg, whose earlier discovery of the immune-stimulatory CpG DNA motif in 1994 provided the scientific foundation for the firm's therapeutic approach. This technology centered on Toll-like receptors (TLRs), which are crucial components of the immune system. Coley's strategy was to create drugs that could stimulate or block these receptors to direct the immune system to combat diseases.
The company's business model was rooted in the research and development of these immunomodulatory drugs and vaccine adjuvants. It established a pipeline of product candidates targeting TLRs 7, 8, and 9, with applications aimed at cancers, allergy and asthma disorders, autoimmune diseases, and infectious diseases. Revenue generation and pipeline advancement were pursued through strategic partnerships and license agreements with major pharmaceutical corporations, including Pfizer, sanofi-aventis, GlaxoSmithKline, and Merck. Before its acquisition, the company had raised at least $55 million in funding from investors such as Venrock and Carlyle AlpInvest.
A significant milestone in the company's history was the acquisition of the majority of 3M's therapeutic TLR cancer programs in June 2007. This deal expanded Coley's intellectual property, adding a portfolio of small molecule candidates targeting TLR7 and TLR8. However, a major setback occurred that same year when Pfizer, a key partner, discontinued development of a promising lung cancer compound, PF-3512676, after Phase III trials showed a lack of additional efficacy. Despite this, Pfizer proceeded to acquire Coley Pharmaceutical Group in a deal announced in November 2007 for an enterprise value of $164 million. The acquisition was completed in early 2008, integrating Coley's technology and pipeline into Pfizer's vaccine and immunotherapeutics strategy.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1997
- Headquarters
- Wellesley, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 23.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Nov 2007 | $164M | $164M | Pfizer | — |
| DEBTDebt | Feb 2007 | $0 | — | Thuja Capital | — |
Growth signals
Latest recorded traffic for Coley Pharmaceutical Group is 0 monthly website visits. Coley Pharmaceutical Group's team declined 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Coley Pharmaceutical Group in the Wellesley ecosystem
The Coley Pharmaceutical Group office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Techno Venture Management- ACAlafi Capital
Qiagen
Series B and later4 investors entered at this stage
Thomas McNerney & Partners
Venrock
Thuja Capital- GVGlobal Life Science Ventures
Other known investors1 additional known investor
Pfizer
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Coley Pharmaceutical Group on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Coley Pharmaceutical Group’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







